Joseph Jones, MD
Internal Medicine · Bossier City, LANPI 1295937936
Payments from drug & device makers
Across 193 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$406
- Lilly USA, LLC$337
- Amgen$296
- AstraZeneca$271
- Johnson & Johnson$157
- Merck$138
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,863100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 35 | $406 |
| Lilly USA, LLC | 22 | $337 |
| Amgen | 25 | $296 |
| AstraZeneca | 15 | $271 |
| Johnson & Johnson | 13 | $157 |
| Merck | 10 | $138 |
| Phathom Pharmaceuticals, Inc. | 6 | $100 |
| Dexcom, Inc. | 2 | $94 |
| Novo Nordisk | 6 | $92 |
| Pfizer | 5 | $88 |
| AbbVie(2 entities) | 5 | $85 |
| Corcept Therapeutics | 3 | $79 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $68 |
| Daiichi Sankyo Inc. | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 5 | $62 |
| Novartis | 4 | $60 |
| Astellas Pharma US Inc | 3 | $50 |
| Boehringer Ingelheim | 3 | $49 |
| Avanir Pharmaceuticals, Inc. | 3 | $46 |
| Abiomed | 2 | $37 |
| Abbott | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Mylan Specialty L.p. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Viatris Specialty LLC | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $14 |
How this compares
$2,863 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $117,374 |
| EliquisApixaban | 107 | $101,686 |
| MounjaroTirzepatide | 72 | $83,078 |
| JardianceEmpagliflozin | 99 | $77,585 |
| EntrestoSacubitril/Valsartan | 99 | $66,028 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $46,871 |
| JanuviaSitagliptin Phosphate | 27 | $38,663 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $28,466 |
| TrulicityDulaglutide | 23 | $27,218 |
| LinzessLinaclotide | 26 | $25,865 |
| Repatha SureclickEvolocumab | 38 | $24,977 |
| XareltoRivaroxaban | 18 | $18,095 |
| MyrbetriqMirabegron | 11 | $14,650 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $9,301 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $9,220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $92 | $117,37496 claims |
| Lilly USA, LLCMounjaro, Trulicity | $337 | $110,29695 claims |
| PfizerEliquis | $88 | $101,686107 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $49 | $86,886110 claims |
| NovartisEntresto | $60 | $66,02899 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $406 | $51,26064 claims |
| MerckJanuvia | $138 | $38,66327 claims |
| AbbVieLinzess | $85 | $25,86526 claims |
| Johnson & JohnsonXarelto | $157 | $18,09518 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $14,65011 claims |
| AstraZenecaSymbicort | $271 | $9,22023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Bossier City
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.